The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Research reveals men skipping prostate cancer screenings are 45% more likely to die from the disease. Evidence from a large ...

In recognition of National Kidney Health Month, Halton Healthcare is the first regional hospital to offer renal (kidney) ...

IceCure Medical (ICCM) announced that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to ...

(NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal ...

PR Newswire CAESAREA, Israel IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel /PRNewswire/ -- IceCure Medi ...